Stem cell therapy is the use of stem cells to prevent diseases like bone marrow transplantation. Stem cells are unspecialized cells that can develop into various types of cells over time.
Stem Cell Therapeutic Market share:
The stem cell therapeutic market is segmented by treatment and geography. On basics of treatment, the largest share is in North America because of the demand for organs has been increasing, and organ transplantation is majorly driving the market share.
Stem Cell Therapeutic Market size:
Stem Cells Market is accounted for USD 14.1 billion in 2017 and expected to grow at a CAGR of 13% to reach USD 15.62 billion by 2024.
North America has the highest market for stem cell therapeutic market because of the increasing demand for organ donors, development of regenerative medicine and research on stem cell therapies are raising the demand for the market. During the forecast period, Asia-Pacific and Europe are going to have the quick growth in the market.
Stem Cell Therapeutic Market growth:
The market for stem cells therapeutic is driven by factors such as development in organ transplantations, regenerative medicine, increase in demand for organs, development of drugs and reimbursement policies increasing the growth of the stem cell therapeutic market.
Stem Cell Therapeutic Market Industrial Analysis:
Stem Cell Therapeutic Market is segmented on the basis of treatment, and geography. In this categorization, the growth of the market is driven by treatment segment classified by syngeneic stem therapy; allogeneic stem therapy, autologous stem therapy. Among other treatments, allogeneic stem therapy is the fastest growing stem cell therapeutic market.
Stem Cell Therapeutic Market Outlook:
Stem cell therapeutic is used to develop new methods for treating diseases such as dementia, organ transplantation, bone marrow treatments, cancer cells, tissues engineering and neural developments for neurological disorders further increased the demand for stem cells therapeutic and its predominant in North America especially the US.
Stem Cell Therapeutic Market Trends:
ViaCyte and BetaLogics have working on stem cell-derived therapy for diabetes. ViaCyte and Janssen Biotech, Inc. have merged into one firm in 2016.
Takara Bio USA Holdings, Inc. has completely acquired the WaferGen Bio-systems, Inc., WaferGen has become a subsidiary of TBUSH as of February 2017.
Stem Cell Therapeutic Market Research Report Includes:
Starting from $2700
Starting from $2700
Starting from $2700
Keep up-to-date with our weekly newsletter, Media Pulse.